These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22698669)

  • 21. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.
    Miao M; Jing X; De Clercq E; Li G
    Drug Des Devel Ther; 2020; 14():2759-2774. PubMed ID: 32764876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinase.
    Shiryaev SA; Cheltsov AV; Strongin AY
    PLoS One; 2012; 7(7):e40029. PubMed ID: 22768327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural analysis of asunaprevir resistance in HCV NS3/4A protease.
    Soumana DI; Ali A; Schiffer CA
    ACS Chem Biol; 2014 Nov; 9(11):2485-90. PubMed ID: 25243902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).
    Imhof I; Simmonds P
    Hepatology; 2011 Apr; 53(4):1090-9. PubMed ID: 21480315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
    Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
    J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus.
    Welsch C; Domingues FS; Susser S; Antes I; Hartmann C; Mayr G; Schlicker A; Sarrazin C; Albrecht M; Zeuzem S; Lengauer T
    Genome Biol; 2008 Jan; 9(1):R16. PubMed ID: 18215275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational study on the drug resistance mechanism of HCV NS3 protease to BMS-605339.
    Wang H; Guo C; Chen BZ; Ji M
    Biotechnol Appl Biochem; 2017 Mar; 64(2):153-164. PubMed ID: 26790544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
    Deutsch M; Papatheodoridis GV
    Curr Opin Investig Drugs; 2010 Aug; 11(8):951-63. PubMed ID: 20721837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective.
    Boonma T; Nutho B; Rungrotmongkol T; Nunthaboot N
    Comput Biol Chem; 2019 Dec; 83():107154. PubMed ID: 31751885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular recognition mechanism and motion of HCV NS3/4A protease with Faldaprevir analogue].
    Liang L; Hu J; Du W; Zuo K; Liu W; Gou X
    Sheng Wu Gong Cheng Xue Bao; 2016 May; 32(5):669-682. PubMed ID: 29019204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
    Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
    J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.
    Ehrenberg AE; Schmuck B; Anwar MI; Gustafsson SS; Stenberg G; Danielson UH
    J Enzyme Inhib Med Chem; 2014 Dec; 29(6):868-76. PubMed ID: 24517372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights into resistance mechanism of hepatitis C virus nonstructural 3/4A protease mutant to boceprevir using umbrella sampling simulation study.
    Behmard E; Barzegari E
    J Biomol Struct Dyn; 2020 Apr; 38(7):1938-1945. PubMed ID: 31146645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.
    Matthew AN; Zephyr J; Nageswara Rao D; Henes M; Kamran W; Kosovrasti K; Hedger AK; Lockbaum GJ; Timm J; Ali A; Kurt Yilmaz N; Schiffer CA
    mBio; 2020 Mar; 11(2):. PubMed ID: 32234812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The resistance mutation R155K in the NS3/4A protease of hepatitis C virus also leads the virus to escape from HLA-A*68-restricted CD8 T cells.
    Salloum S; Kluge SF; Kim AY; Roggendorf M; Timm J
    Antiviral Res; 2010 Aug; 87(2):272-5. PubMed ID: 20488208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unraveling the mechanisms of Sofosbuvir resistance in HCV NS3/4A protease: Structural and molecular simulation-based insights.
    Shahab M; Khan A; Khan SA; Zheng G
    Int J Biol Macromol; 2024 May; 267(Pt 2):131629. PubMed ID: 38631585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two years' persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy.
    Colson P; Gérolami R
    J Infect Dis; 2011 May; 203(9):1341-2; author reply 1342-3. PubMed ID: 21459820
    [No Abstract]   [Full Text] [Related]  

  • 39. The competitive binding between inhibitors and substrates of HCV NS3/4A protease: a general mechanism of drug resistance.
    Guan Y; Sun H; Li Y; Pan P; Li D; Hou T
    Antiviral Res; 2014 Mar; 103():60-70. PubMed ID: 24462696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease.
    Rajagopalan R; Pan L; Schaefer C; Nicholas J; Lim S; Misialek S; Stevens S; Hooi L; Aleskovski N; Ruhrmund D; Kossen K; Huang L; Yap S; Beigelman L; Serebryany V; Liu J; Sastry S; Seiwert S; Buckman B
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.